申请人:Kyowa Hakko Kirin Co., Ltd.
公开号:EP3002283A1
公开(公告)日:2016-04-06
The present invention relates to a pharmaceutical composition comprising, as the active ingredient, a thiazole derivative represented by a formula (IA), or a pharmaceutically acceptable salt thereof:
wherein:
R1A represents substituted or unsubstituted furyl (excluding a group selected from 5-phosphonofuran-2-yl and 5-nitrofuran-2-yl);
R12 represents substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C1-10 alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted alicyclic heterocyclic-alkyl, or substituted or unsubstituted aromatic heterocyclic-alkyl;
n is 0;
R3A represents a hydrogen atom; and
R2A represents -COR8 (wherein R8 represents substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group).
本发明涉及一种药物组合物,其活性成分包括由式(IA)表示的噻唑衍生物或其药学上可接受的盐:
其中
R1A 代表取代或未取代的呋喃基(不包括选自 5-膦酰基呋喃-2-基和 5-硝基呋喃-2-基的基团);
R12 代表取代或未取代的 C1-10 烷基、取代或未取代的 C1-10 烷氧基、取代或未 取代的环烷基、取代或未取代的芳基、取代或未取代的芳烷基、取代或未 取代的脂环杂环基团、取代或未取代的芳香杂环基团、取代或未取代的脂 环杂环烷基或取代或未取代的芳香杂环烷基;
n 为 0;
R3A 代表氢原子;以及
R2A 代表-COR8(其中 R8 代表取代或未取代的环烷基、取代或未取代的芳基、取代或未取代的脂环杂环基团或取代或未取代的芳香杂环基团)。